Accessibility Menu
Xenon Pharmaceuticals logo

Xenon Pharmaceuticals

(NASDAQ) XENE

Current Price$66.94
Market Cap$6.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+538%
5 Year+270%
1 Year+112%
1 Month+29%
Xenon Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 66.982026-07-16
Xenon Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.61%USD 70.962026-07-09
1 month+28.83%USD 51.992026-06-16
3 month+12.19%USD 59.702026-04-17
Year to date+49.44%USD 44.822025-12-31
1 year+111.83%USD 31.622025-07-16
3 year+71.22%USD 39.122023-07-17
5 year+270.46%USD 18.082021-07-16
Since inception+537.9%USD 10.502014-11-05

Xenon Pharmaceuticals Financials at a Glance

Market Cap

$6.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$383.17M

EPS (TTM)

-$4.70

P/E Ratio

-14.24

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$66.94

Volume

289.149

Open

$67.70

Previous Close

$66.98

Daily Range

$65.98 - $67.76

52-Week Range

$30.00 - $72.66

Estimated Earnings Date

Aug 10, 2026

XENE News

BuyAlert-Purple.png

What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

Jonathan PoncianoMay 18, 2026
SellAlert-Red.png

Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know

Jonathan PoncianoMar 27, 2026
BuyAlert-Green.png

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough

Jonathan PoncianoMar 13, 2026
SellAlert-Green.png

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data

Jonathan PoncianoFeb 19, 2026
investment-advisor-pitching-stocks-to-buy-getty

3 Growth Stocks Near 52-Week Highs to Buy Anyway

Cory RenauerOct 14, 2021
investor-looking-hard-for-stocks-to-buy-getty

Is Xenon Pharmaceuticals a Good Stock to Buy Now?

Cory RenauerOct 5, 2021
3d rocket model

Why Xenon Pharmaceuticals Stock Is Screaming Higher Today

George Budwell, PhDOct 4, 2021
financial health stethoscope money cash hundred bills medical healthcare

Is Now a Good Time To Buy Neurocrine Biosciences?

James HalleyMay 14, 2020
Page 1

XENE: Motley Fool Moneyball Superscore

74

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xenon Pharmaceuticals

Xenon helps people with brain disorders like epilepsy and depression. They develop new medicines to stop seizures and improve mood. The company focuses on patients who need better treatment options.

What is in the Medicine Cabinet?

  • Azetukalner: Experimental medicine for epilepsy and depression currently undergoing Phase 3 testing.
  • Pain Treatments: Early-stage candidates XEN1701 and XEN1120 designed to block pain signals in the nerves.
  • Partnered Programs: Epilepsy candidate NBI-921355 developed in collaboration with Neurocrine Biosciences for specific seizure types.
  • XEN007: Calcium channel modulator being evaluated in Phase 2 trials for central nervous system disorders.

Partnering for New Cures

  • Acquired the epilepsy drug azetukalner from 1st Order Pharmaceuticals in April 2017.
  • Formed a partnership with Neurocrine Biosciences in 2019 to develop novel treatments for epilepsy.
  • Raised $707.6 million in March 2026 through an underwritten offering led by J.P. Morgan Securities LLC.
  • Refreshed an at-the-market sales program in February 2026 to potentially issue up to $400 million in shares.
  • Collaborated with Flexion Therapeutics to develop pain treatments such as PCRX301 for post-operative recovery.

Mastering the Body's Signals

The company specializes in ion channel biology to control nerve signals in the body. This approach helps them design highly specific drugs that aim to reduce unwanted side effects.

A Look at the Books

  • Collaboration revenue fell to $0 in Q1 2026, down 100% from $7.5 million in Q1 2025.
  • Net loss was $102.3 million in Q1 2026, deepening 57.3% from the $65 million loss in Q1 2025.
  • Free cash flow reached -$89 million in Q1 2026, worsening 44.3% from -$61.7 million in Q1 2025.
  • Cash and marketable securities totaled $1.34 billion as of March 31, 2026, following significant capital raises.

The Road Ahead

Xenon has transitioned into a late-stage clinical company with multiple drug candidates in final testing phases. Its future depends on successfully gaining regulatory approval and moving into commercial drug sales.

AI Generated • May 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

370

CEO

Ian C. Mortimer, MBA

Website

www.xenon-pharma.com

Headquarters

Burnaby, BC V5G 4W8, CA

XENE Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-49.23%

Return on Capital

-63.26%

Return on Assets

-27.63%

Earnings Yield

-7.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

96.67M

Volume

289.149

Avg. Volume

1.43M

Financials (TTM)

Gross Profit

-$78.30M

Operating Income

-$412.66M

EBITDA

-$399.03M

Operating Cash Flow

-$306.36M

Capital Expenditure

-$889.00K

Free Cash Flow

-$307.25M

Cash & ST Invst.

$1.09B

Total Debt

$7.49M

Xenon Pharmaceuticals Performance Analysis

Xenon Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9,434,000-48.8%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 7,500,000N/A
Xenon Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Xenon Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.0616.8%
20232023-12-31USD -2.7332.1%
20242024-12-31USD -3.0110.3%
20252025-12-31USD -4.3645.1%
Xenon Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-28.9%
Q32025-09-30-7.5%
Q42025-12-31-13.9%
Q12026-03-3110.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$6.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$20.49M

N/A

Employees

316

N/A

Net Income

-$102.30M

-57.3%

EBITDA

-$111.74M

-55.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.09B

+99.2%

Total Debt

$7.49M

-13.6%

Accounts Receivable

$1.17M

-86.5%

Inventory

$0.00

N/A

Long Term Debt

$5.93M

-18.7%

Short Term Debt

$1.56M

+13.0%

Return on Assets

-27.63%

N/A

Return on Invested Capital

-30.64%

N/A

Free Cash Flow

-$89.03M

-44.3%

Operating Cash Flow

-$88.90M

-44.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNTACentessa Pharmaceuticals plc
$40.50+0.00%
SRRKScholar Rock Holding Corporation
$51.73-4.27%
CGONCG Oncology Inc.
$69.50-4.79%
TVTXTravere Therapeutics, Inc.
$55.28-2.57%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.51-0.12%
NOKNokia
$10.38-0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.74-0.05%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.89+0.05%

Questions About XENE

What is the current price of Xenon Pharmaceuticals?

Xenon Pharmaceuticals is trading at $66.98 per share.

What is the 52-week range for Xenon Pharmaceuticals?

Over the past 52 weeks, Xenon Pharmaceuticals has traded between $30.00 and $72.66.

How much debt does Xenon Pharmaceuticals have?

As of the most recent reporting period, Xenon Pharmaceuticals reported total debt of $7.49M.

How much cash does Xenon Pharmaceuticals have on hand?

Xenon Pharmaceuticals reported $545.87M in cash and cash equivalents in its most recent financial results.

What is Xenon Pharmaceuticals’s dividend yield?

Xenon Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services